SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Takehiro Kawata, Akira Kanamori, Akira Kubota, Hajime Maeda, Hikaru Amamiya, Masahiko Takai, Hideaki Kaneshige, Fuyuki Minagawa, Kotaro Iemitsu, Mizuki Kaneshiro, Masashi Ishikawa, Hiroshi Takeda, Tetsurou Takuma, Atsuko Mokubo, Hideo Machimura, Mitsuo Obana, Masaaki Miyakawa, Yoshikazu Naka, Yasuo Terauchi, Masao Toyoda, Daisuke Suzuki, Yasushi Tanaka, Ikuro Matsuba, Clinical effects of liraglutide on diabetes control in Japanese type 2 diabetes mellitus patients, Diabetology International, 2014, 5, 2, 98

    CrossRef

  2. 2
    Stefan Harmuth, Marlene Wewalka, Jens Juul Holst, Romina Nemecek, Sabine Thalhammer, Rainer Schmid, Klaus Sahora, Michael Gnant, Johannes Miholić, Distal Gastrectomy in Pancreaticoduodenectomy is Associated with Accelerated Gastric Emptying, Enhanced Postprandial Release of GLP-1, and Improved Insulin Sensitivity, Journal of Gastrointestinal Surgery, 2014, 18, 1, 52

    CrossRef

  3. 3
    Jui-Hung Chen, Wen-Hao Tang, Chien-Hsing Lee, Effective weight loss after treatment with a glucagon-like peptide-1 receptor agonist in a morbidly obese and diabetic patient before bariatric surgery: a case report, Journal of Medical Case Reports, 2014, 8, 1, 304

    CrossRef

  4. 4
    Dijian Shen, Huan Ye, Yuedong Wang, Yun Ji, Xiaoli Zhan, Jinhui Zhu, Laparoscopic greater curvature plication: Surgical techniques and early outcomes of a Chinese experience, Surgery for Obesity and Related Diseases, 2014, 10, 3, 432

    CrossRef

  5. 5
    Patricio López-Jaramillo, Carlos Velandia, Gabriela Castillo, Tatiana Sánchez, Julie Álvarez, Análogos de incretina e inhibidores de la DPP-4: ¿qué papel desempeñan en la prevención primaria de las enfermedades cardiovasculares?, Revista Colombiana de Cardiología, 2013, 20, 5, 287

    CrossRef

  6. 6
    M. Seghieri, E. Rebelos, A. Gastaldelli, B. D. Astiarraga, A. Casolaro, E. Barsotti, A. Pocai, M. Nauck, E. Muscelli, E. Ferrannini, Direct effect of GLP-1 infusion on endogenous glucose production in humans, Diabetologia, 2013, 56, 1, 156

    CrossRef

  7. You have free access to this content7
    R. S. Rao, R. Yanagisawa, S. Kini, Insulin resistance and bariatric surgery, Obesity Reviews, 2012, 13, 4
  8. 8
    Cornelia B. Landersdorfer, Yan-Ling He, William J. Jusko, Mechanism-based population modelling of the effects of vildagliptin on GLP-1, glucose and insulin in patients with type 2 diabetes, British Journal of Clinical Pharmacology, 2012, 73, 3
  9. 9
    Joy Cuthbertson, Steven Patterson, Finbarr P. O'Harte, Patrick M. Bell, Addition of metformin to exogenous glucagon-like peptide–1 results in increased serum glucagon-like peptide–1 concentrations and greater glucose lowering in type 2 diabetes mellitus, Metabolism, 2011, 60, 1, 52

    CrossRef

  10. 10
    Asger Lund, Filip K Knop, Tina Vilsbøll, Emerging GLP-1 receptor agonists, Expert Opinion on Emerging Drugs, 2011, 16, 4, 607

    CrossRef

  11. 11
    Annesofie Faurschou, Claus Zachariae, Lone Skov, Tina Vilsbøll, Filip K. Knop, Gastric bypass surgery: Improving psoriasis through a GLP-1-dependent mechanism?, Medical Hypotheses, 2011, 77, 6, 1098

    CrossRef

  12. 12
    Chiara Nediani, Laura Raimondi, Elisabetta Borchi, Elisabetta Cerbai, Nitric Oxide/Reactive Oxygen Species Generation and Nitroso/Redox Imbalance in Heart Failure: From Molecular Mechanisms to Therapeutic Implications, Antioxidants & Redox Signaling, 2011, 14, 2, 289

    CrossRef

  13. 13
    Mikkel Christensen, Filip K Knop, Tina Vilsbøll, The GetGoal clinical trial program of lixisenatide, a once-daily GLP-1 receptor agonist, Expert Review of Endocrinology & Metabolism, 2011, 6, 4, 513

    CrossRef

  14. 14
    Milan K. Piya, Abd A. Tahrani, Anthony H. Barnett, Emerging treatment options for type 2 diabetes, British Journal of Clinical Pharmacology, 2010, 70, 5
  15. 15
    David A. Taylor-Fishwick, Gary L. Pittenger, Harnessing the Pancreatic Stem Cell, Endocrinology and Metabolism Clinics of North America, 2010, 39, 4, 763

    CrossRef

  16. 16
    Nicole R. Pinelli, Carol L. Moore, Sarah Tomasello, Incretin-based Therapy in Chronic Kidney Disease, Advances in Chronic Kidney Disease, 2010, 17, 5, 439

    CrossRef

  17. 17
    Anne Flint, Khalil Nazzal, Pawel Jagielski, Charlotte Hindsberger, Milan Zdravkovic, Influence of hepatic impairment on pharmacokinetics of the human GLP-1 analogue, liraglutide, British Journal of Clinical Pharmacology, 2010, 70, 6
  18. 18
    Baptist Gallwitz, Inkretine: Gibt es kardiovaskuläre Effekte?, Herz, 2010, 35, 3, 130

    CrossRef

  19. 19
    Mikkel Christensen, Filip K. Knop, Once-Weekly GLP-1 Agonists: How Do They Differ from Exenatide and Liraglutide?, Current Diabetes Reports, 2010, 10, 2, 124

    CrossRef

  20. 20
    Kristine J. Hare, Filip K. Knop, Incretins and Insulin Secretion, 2010,

    CrossRef

  21. 21
    David J Grieve, Roslyn S Cassidy, Brian D Green, Emerging cardiovascular actions of the incretin hormone glucagon-like peptide-1: potential therapeutic benefits beyond glycaemic control?, British Journal of Pharmacology, 2009, 157, 8
  22. 22
    J. Cuthbertson, S. Patterson, F. P. M. O’Harte, P. M. Bell, Investigation of the effect of oral metformin on dipeptidylpeptidase-4 (DPP-4) activity in Type 2 diabetes, Diabetic Medicine, 2009, 26, 6
  23. 23
    F. K. Knop, Resolution of type 2 diabetes following gastric bypass surgery: involvement of gut-derived glucagon and glucagonotropic signalling?, Diabetologia, 2009, 52, 11, 2270

    CrossRef

  24. 24
    A. N. Paisley, M. W. Savage, P. G. Wiles, Stabilizing effect of exenatide in a patient with C-peptide-negative diabetes mellitus, Diabetic Medicine, 2009, 26, 9
  25. 25
    Stanley Schwartz, Targeting the pathophysiology of type 2 diabetes: rationale for combination therapy with pioglitazone and exenatide, Current Medical Research and Opinion, 2008, 24, 11, 3009

    CrossRef

  26. 26
    David A. Taylor-Fishwick, Gary L. Pittenger, Aaron I. Vinik, Transplantation and beyond, Drug Development Research, 2008, 69, 3
  27. 27
    Laurie L. Baggio, Daniel J. Drucker, Biology of Incretins: GLP-1 and GIP, Gastroenterology, 2007, 132, 6, 2131

    CrossRef

  28. 28
    Brian D. Green, Peter R. Flatt, Incretin hormone mimetics and analogues in diabetes therapeutics, Best Practice & Research Clinical Endocrinology & Metabolism, 2007, 21, 4, 497

    CrossRef

  29. 29
    Paul E. Wiedeman, Progress in Medicinal Chemistry Volume 45, 2007,

    CrossRef

  30. 30
    Thomas W. von Geldern, James M. Trevillyan, “The next big thing” in diabetes: clinical progress on DPP-IV inhibitors, Drug Development Research, 2006, 67, 8
  31. 31
    I. Valverde, J. Cancelas, M.L. Villanueva-Peñacarrillo, El GLP-1: acción biológica y posibles efectos terapéuticos, Endocrinología y Nutrición, 2006, 53, 4, 256

    CrossRef

  32. 32
    A. C. Heijboer, H. Pijl, A. M. Van den Hoek, L. M. Havekes, J. A. Romijn, E. P. M. Corssmit, Gut–Brain Axis: Regulation of Glucose Metabolism, Journal of Neuroendocrinology, 2006, 18, 12
  33. 33
    Paul E. Wiedeman, James M. Trevillyan, Dipeptidyl peptidase IV inhibitors for type 2 diabetes and metabolic syndrome, Drug Discovery Today: Therapeutic Strategies, 2005, 2, 2, 143

    CrossRef

  34. 34
    M. N. Feinglos, M. F. Saad, F. X. Pi-Sunyer, B. An, O. Santiago, Effects of liraglutide (NN2211), a long-acting GLP-1 analogue, on glycaemic control and bodyweight in subjects with Type 2 diabetes, Diabetic Medicine, 2005, 22, 8
  35. 35
    C. M. Rotella, L. Pala, E. Mannucci, Glucagon-like peptide 1 (GLP-1) and metabolic diseases, Journal of Endocrinological Investigation, 2005, 28, 10, 746

    CrossRef

  36. 36
    Shareen Forbes, May Moonan, Stephen Robinson, Victor Anyaoku, Michael Patterson, Kevin G. Murphy, Mohammed A. Ghatei, Stephen R. Bloom, Desmond G. Johnston, Impaired circulating glucagon-like peptide-1 response to oral glucose in women with previous gestational diabetes, Clinical Endocrinology, 2005, 62, 1
  37. 37
    V. Ionut, K. Hucking, I. F. Liberty, R. N. Bergman, Synergistic effect of portal glucose and glucagon-like peptide-1 to lower systemic glucose and stimulate counter-regulatory hormones, Diabetologia, 2005, 48, 5, 967

    CrossRef

  38. 38
    Octaviano A Roges, Marilyn Baron, Athena Philis-Tsimikas, The incretin effect and its potentiation by glucagon-like peptide 1-based therapies: a revolution in diabetes management, Expert Opinion on Investigational Drugs, 2005, 14, 6, 705

    CrossRef

  39. 39
    Laurie L. Baggio, Daniel J. Drucker, Glucagon-like peptide-1 and glucagon-like peptide-2, Best Practice & Research Clinical Endocrinology & Metabolism, 2004, 18, 4, 531

    CrossRef

  40. 40
    Bo Ahrén, Gut peptides and type 2 diabetes mellitus treatment, Current Diabetes Reports, 2003, 3, 5, 365

    CrossRef

  41. 41
    Jens Juul Holst, Therapy of type 2 diabetes mellitus based on the actions of glucagon-like peptide-1, Diabetes/Metabolism Research and Reviews, 2002, 18, 6
  42. 42
    E. Mannucci, A. Ognibene, F. Cremasco, G. Bardini, A. Mencucci, E. Pierazzuoli, S. Ciani, A. Fanelli, G. Messeri, C. M. Rotella, Glucagon-like peptide (GLP)-1 and leptin concentrations in obese patients with Type 2 diabetes mellitus, Diabetic Medicine, 2000, 17, 10
  43. 43
    Bo Ahrén, Jens J Holst, Hans Mårtensson, Börk Balkan, Improved glucose tolerance and insulin secretion by inhibition of dipeptidyl peptidase IV in mice, European Journal of Pharmacology, 2000, 404, 1-2, 239

    CrossRef

  44. 44
    Bo Ahrén, Glucagon-like peptide-1 (GLP-1): A gut hormone of potential interest in the treatment of diabetes, BioEssays, 1998, 20, 8